For the week of September 29:

The FDA sent letters to five pharmaceutical companies that market ADHD drugs, warning them about incomplete, false or misleading advertising.

Johnson & Johnson’s Concerta and Shire’s Adderall XR were cited, with the agency mentioning a YouTube video featuring Extreme Makeover: Home Edition’s Ty Pennington, the drug’s spokesperson.

According to Dow Jones Newswires: “The FDA said ‘this video overstates the efficacy of Adderall XR by implying that this product will transform patients’ lives and improve their confidence.’ The agency also said Shire violated FDA regulations for not submitting the YouTube video to the agency prior to using the video.

In a statement, Shire said the video was posted in error and was meant to be posted on Shire’s site with the appropriate dosing and indication information for Adderall.’

Also:

Johnson & Johnson finds transparency about drug studies may have limited share damage after the FDA reported that Eprex, approved for anemia treatment and and being tested in high doses to treat patients who have had ischemic strokes, had a high incidence of death.

Slate looks at the ad for Organon’s NuvaRing, which aims to portray birth control bills as burdensome and traditional.

Pharma spending on advertising, including unbranded health education campaigns, is on the decline for the first time, says Brandweek.